NCT04613557: Phase 1: Safety, Activity and Cell Kinetics of CYAD-211 in RRMM Myeloma (IMMUNICY-1)

NCT04613557: Phase 1: Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma (IMMUNICY-1)

Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma (IMMUNICY-1)

The purpose of the IMMUNICY-1 study is to assess the safety, activity and cell kinetics of CYAD-211 in adults with relapsed or refractory multiple myeloma after a lymphodepletion regimen with fludarabine and/or cyclophosphamide

Sponsor

Celyad Oncology SA

---

ClinicalTrials.gov Identifier: NCT04613557

Official Title: Open-label Phase I, Multi-center Study to Determine the Recommended Dose of CYAD-211 After a Non-myeloablative Preconditioning Chemotherapy in Multiple Myeloma Patients With Relapsed or Refractory Disease

First Posted : November 3, 2020

Click here to see details on ClinicalTrials.gov

---

Biological: CYAD-211

Drug: Endoxan

Drug: Fludara

---

CYAD 211

Allogeneic shRNA-based Anti-BCMA CAR T-cells CYAD-211 (Code C176885)

Allogeneic shRNA-based Anti-BCMA CAR T-cells CYAD-211

Allogeneic shRNA-based Anti-BCMA CAR-T Cells CYAD-211

CYAD 211

CYAD-211

CYAD211

---

Locations

United States, Florida

United States, New York

Europe

Belgium